- -

Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer

Show simple item record

Files in this item

dc.contributor.author Jantus Lewintre, Eloisa es_ES
dc.date.accessioned 2017-01-16T13:59:28Z
dc.date.available 2017-01-16T13:59:28Z
dc.date.issued 2013
dc.identifier.issn 0027-8874
dc.identifier.uri http://hdl.handle.net/10251/76886
dc.description https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776260/ es_ES
dc.description.abstract [EN] Background There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of complement activation fragments. Methods We assessed complement activation in four bronchial epithelial and seven lung cancer cell lines. C4d, a degradation product of complement activation, was determined in 90 primary lung tumors; bronchoalveolar lavage supernatants from patients with lung cancer (n = 50) and nonmalignant respiratory diseases (n = 22); and plasma samples from advanced (n = 50) and early lung cancer patients (n = 84) subjects with inflammatory lung diseases (n = 133), and asymptomatic individuals enrolled in a lung cancer computed tomography screening program (n = 190). Two-sided P values were calculated by Mann-Whitney U test. Results Lung cancer cells activated the classical complement pathway mediated by C1q binding that was inhibited by phosphomonoesters. Survival was decreased in patients with high C4d deposition in tumors (hazard ratio [HR] = 3.06; 95% confidence interval [CI] = 1.18 to 7.91). C4d levels were increased in bronchoalveolar lavage fluid from lung cancer patients compared with patients with nonmalignant respiratory diseases (0.61 +/- 0.87 vs 0.16 +/- 0.11 mu g/mL; P < .001). C4d levels in plasma samples from lung cancer patients at both advanced and early stages were also increased compared with control subjects (4.13 +/- 2.02 vs 1.86 +/- 0.95 mu g/mL, P < 0.001; 3.18 +/- 3.20 vs 1.13 +/- 0.69 mu g/mL, P < .001, respectively). C4d plasma levels were associated with shorter survival in patients at advanced (HR = 1.59; 95% CI = 0.97 to 2.60) and early stages (HR = 5.57; 95% CI = 1.60 to 19.39). Plasma C4d levels were reduced after surgical removal of lung tumors (P < .001) and were associated with increased lung cancer risk in asymptomatic individuals with (n = 32) or without lung cancer (n = 158) (odds ratio = 4.38; 95% CI = 1.61 to 11.93). Conclusions Complement fragment C4d may serve as a biomarker for early diagnosis and prognosis of lung cancer. es_ES
dc.description.sponsorship This work was supported by UTE project CIMA; the Spanish Government (grant numbers ISCIII-RTICC RD06/0020/0066, RD06/0020/1024, RD12/0036/0025, RD12/0036/0040, RD12/0036/0062, PI08/0923, PI10/01652, PI10/00166, and PI11/00618); the European Regional Development Fund; the European Community’s Seventh Framework Programme (HEALTH-F2-2010-258677- CURELUNG); and the Early Detection Research Network from the National Cancer Institute (grant number U01 CA152662). This work was supported (in part) by a grant (RD12/0036/XXXX) from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness & European Regional Development Fund “Una manera de hacer Europa”.
dc.language Inglés es_ES
dc.publisher Oxford University Press (OUP) es_ES
dc.relation UTE project CIMA es_ES
dc.relation ISCIII-RTICC/RD06/0020/0066 es_ES
dc.relation ISCIII/RD12/0036/XXXX es_ES
dc.relation ISCIII-RTICC/RD06/0020/1024 es_ES
dc.relation ISCIII-RTICC/RD12/0036/0025 es_ES
dc.relation ISCIII-RTICC/RD12/0036/0040
dc.relation ISCIII-RTICC/RD12/0036/0062
dc.relation ISCIII-RTICC/PI08/0923
dc.relation ISCIII-RTICC/PI10/01652
dc.relation ISCIII-RTICC/PI10/00166
dc.relation ISCIII-RTICC/PI11/00618
dc.relation.ispartof JNCI: Journal of the National Cancer Institute es_ES
dc.rights Reserva de todos los derechos es_ES
dc.subject Lung cancer es_ES
dc.subject Factor-h es_ES
dc.subject Immune-response es_ES
dc.subject Cells es_ES
dc.subject Inhibition es_ES
dc.subject Expression es_ES
dc.subject Pathway es_ES
dc.subject System es_ES
dc.subject Confer es_ES
dc.subject C1Q es_ES
dc.subject Diagnosis es_ES
dc.subject.classification MICROBIOLOGIA es_ES
dc.title Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1093/jnci/djt205
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/258677 es_ES
dc.rights.accessRights Abierto es_ES
dc.contributor.affiliation Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural es_ES
dc.description.bibliographicCitation Jantus Lewintre, E. (2013). Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. JNCI: Journal of the National Cancer Institute. 105:1385-1393. doi:10.1093/jnci/djt205 es_ES
dc.description.accrualMethod Senia es_ES
dc.relation.publisherversion https://dx.doi.org/10.1093/jnci/djt205 es_ES
dc.description.upvformatpinicio 1385 es_ES
dc.description.upvformatpfin 1393 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 105 es_ES
dc.relation.senia 318762 es_ES
dc.identifier.eissn 1460-2105
dc.identifier.pmid 23940286 en_EN
dc.identifier.pmcid PMC3776260 en_EN
dc.contributor.funder European Commission
dc.contributor.funder Instituto de Salud Carlos III
dc.contributor.funder Ministerio de Economía y Competitividad


This item appears in the following Collection(s)

Show simple item record